Stockwatch: GSK And AstraZeneca Rush Into Each Other’s Back Yards
Perhaps They Should Tend Their Own Gardens
It is one thing to aspire to build a rival to another company’s banner therapeutic franchise, but quite another to start from the ground up, especially when your form in that area is mixed.
You may also be interested in...
GlaxoSmithKline’s third quarter results included a 9% decline in sales in its vaccine business, but this was offset by tight cost controls and restructuring benefits; the company expects to continue investing in its pipeline and new product launches.
In a wilderness period for biotech stocks, platform company revenues may offer investors less volatile biotech exposure. They are unlikely to shepherd an exit from the current doldrums, though.
Biotech has always been a volatile sector, and it is important for investors to recognize the phases its stocks go through. In particular, the journey through the post-bubble wilderness can be a protracted affair.